Featured Stories
Brexit To And Fro Continues Into Fresh Decade
Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI
The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.

Denmark Offers One-Stop-Shop For Clinical Trials
Denmark’s Trial Nation Portal was established in 2018 with government backing and the aim of luring clinical trials to the country.
Latest News
Recent Issues
Growth Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Growth
Changing China Is Opening Up For Health Care Entrants
The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.
Taking Aim At Advanced Therapies
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.
PureTech’s Problem-Solving Skills Target The BIG Picture
PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.
Innovation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Innovation
C-Suite Snippets: Behind The Scenes At Gates Medical Research Institute
In case you missed it: catch up with snippets from interviews recently published by In Vivo.
Global Health Systems Are Learning To Embrace AI As A Force For Good
The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.
Accessing CAR-T Therapies
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Leadership Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Leadership
Execs On The Move, November 2019
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Gates Foundation Plots A Fresh Metric For Market Access: Lives Saved
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.
Welcome To Alexion 2.0
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
From The Archives
Beyond The Watershed: Gene Therapy Investment And Promise
Janet Lambert, CEO of the Alliance of Regenerative Medicines recently spoke to In Vivo about the tremendous levels of investment the cell and gene therapy industries are attracting, as well as reasons why Europe excels at incubating advanced product development.
Cell And Gene Therapy Logistics Requires Early Planning
It has become standard practice for manufacturing to get early attention in the cell and gene therapy development, but logistics is often not considered until closer to commercialization, which could be a strategic mistake given the speed with which new treatments are being approved.
Market Access Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
C-Suite Snippets: Behind The Scenes At Gates Medical Research Institute
In case you missed it: catch up with snippets from interviews recently published by In Vivo.
Gates MRI CEO Penny Heaton Speaks …
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
We Need To Talk – When To Get Early Scientific Advice
Hearing direct from HTA agencies on what evidence they want to see is now an option through early dialogue. With many options for early dialogue available, it is hard for companies to know whether to get advice, from which agency and how to get the most out of the dialogue.
Market Intelligence Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Intelligence
Generics Leaders Trade Places At The Top
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.
Gene Therapy Manufacturers Are Highly Sought Acquisition Targets
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
Deals Shaping The Medical Industry, December 2019
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.